Gail Cawkwell - Jul 1, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Signature
/s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol
ACRS
Transactions as of
Jul 1, 2023
Transactions value $
-$56,071
Form type
4
Date filed
7/5/2023, 04:23 PM
Previous filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +15K 15K Jul 1, 2023 Direct F1
transaction ACRS Common Stock Tax liability -$56.1K -5.41K -36.05% $10.37 9.59K Jul 1, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -15K -25% $0.00 45K Jul 1, 2023 Common Stock 15K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 The shares underlying these restricted stock units vest in four equal annual installments beginning on July 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.